Abstract
Introduction
High levels of glucose can damage a variety of cells-an effect known as glucotoxicity. Thus, diminishing glucotoxicity by tight glycemic control is crucial for optimizing treatment of diabetes. Evidence has been provided by landmark trials that chronic sustained hyperglycemia is related to vascular diabetes complications. But the mechanisms how hyperglycemia gives rise to the development of disease complications is different for type 1 (T1D) and type 2 diabetes (T2D). Intensive control of glycemia, if started in T1D patients with short disease duration, resulted in recovery of pancreatic ß-cells and reduced micro-and
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Romanian Journal of Diabetes Nutrition & Metabolic Diseases / Vol. 23 / no. 4 / 2016 macrovascular morbidity [1] . And in T2D, lowering of glucose protects against microvascular complications, cataracts, and neuropathy but has shown only modest effects on reduction of cardiovascular diabetes complications [2] . There is no doubt however, that tight control of glycemia early after the disease onset has a durable effect (legacy effect) on complications. Thus, standardized glycemic biomarkers are required, which should also be useful as surrogate measures to assess the risk of late complications of diabetes.
The results of The Action to Control Cardiovascular Risk in Diabetes (ACCORD) and the Action in Diabetes and Vascular Disease: Pereterax g + Diamicron Modified Release
Controlled Evaluation (ADVANCE) trials suggested that levels of hemoglobin A1c (HbA1c) should be individualized according to the patients´ health status to prevent hypoglycemia; patients with older age and extensive comorbidities require less rigorous target levels [3] . In a post-trial evaluation (ADVANCE-ON), strict glucose control was also associated with long-term reduced end-stage kidney disease [4] . Although HbA1c levels predict long-term outcomes and correlate with morbidity and mortality in people with T1D and T2D, associations with macrovascular end points were weaker than with microvascular end points. 
Key markers of glycemic control and potential risk predictors
Glycemic biomarkers are a prerequisite for guiding diabetes therapy in clinical practice and serve as surrogate measures for diabetes complications (Table 1 ). In addition to HbA1c, fructosamine and glycated albumin may provide advantages under specific clinical situations. These markers, will not be dealt with in the present review; they reflect shorter-term glycemic control than HbA1c. 
HbA1c
Hemoglobin is a protein molecule; and its nonenzymatic glycation can occur at several amino acid residues. The glycation process is slow, depends on the ambient glucose concentration, and results in several adducts of hemoglobin A. HbA1c, being the most important component among the hemoglobin adducts, is considered the gold standard for long-term glycemic control and guiding diabetes therapy in conjunction with self-monitored blood glucose (SMBG). The HbA1c analysis from dried blood samples has increased the availability of testing [22] The mismatches might chiefly be explained by differences in intracellular glycation rates (glycation gap) [29] . In about 15-25% of patients, overall glycemia is not adequately reflected by HbA1c levels. Among the various clinical conditions that could interfere with HbA1c measurements are, for example, high red cell turnover, hemolytic disorders, blood transfusion, chronic diseases of kidneys or liver [28] , and drug treatment. These circumstances require glycated albumin or fructosamine to be considered as alternative control metrics. Another limitation of HbA1c is certainly the lacking, respectively, weak correlation with hypoglycemia and glycemic variability (GV). HbA1c is strongly correlated with chronic sustained hyperglycemia [30] , whereas glycemic excursions largely escape detection, as indicated by the small correlation coefficients with commonly used GV metrics. This seems to be critical for clinical decisions and especially for adjustment of insulin therapy in some diabetic patients.
The use of fasting, postprandial, and mean glucose
Besides HbA1c measurement, estimation of glucose exposure may be useful for monitoring the effects of exercise, food intake, and efficacy of antidiabetic medications. Both fasting (FBG) and postprandial blood glucose (PPG) are measures for individual assessment of glycemic control and allow lifestyle modification, even though the relative contributions of the two measures change with increasing HbA1c values [31] . Figure 1 shows that, as patients approach their glycemic target (HbA1c < 7.0%), PPG plays a greater part than FPG in the overall glycemia. About the relationship of FPG or 2h plasma glucose (PG) with regard to diabetes mortality, the data from the Baltimore Longitudinal Study on Aging indicated that levels of FPG, exceeding 7.0 mmol/l, increased the mortality risk; and the 2hPG, if added, augments the predictive power to that of FPG alone [32] . Also in the Australian Diabetes, Obesity, and Life Style Study [10] , impaired fasting glucose emerged as an independent predictor for cardiovascular mortality. A recent meta-analysis showed that lowering of FPG levels was related with decreased cardiovascular mortality, and PPG data pointed in the same direction [11] . Furthermore, observational studies showed that high PPG concentrations increased the risk of cardiovascular events approximately threefold [33] . The Diabetes Intervention study [34] in T2D disclosed the deleterious relationship between increased PPG levels (>10 mmol/l) and higher risk of cardiovascular events; while reduction below this level was shown to decrease rates of myocardial infarction and death. That PPG was a stronger predictor of cardiovascular events than FPG was confirmed in an excellent follow-up study [ When it comes to assessment of actual glucose exposure, mean glucose (average glucose) is a suitable metric that allows easy evaluating the quality of diabetes control by both clinicians and patients over shorter time intervals than with HbA1c. And it is closely correlated with the risk of cardiovascular diabetes complications [9] .
Measures of glucose variability
Clinical observations in continuouslymonitored subjects with TD1 and TD2, even if they present with good glycemic control, disclosed that glucose profile dynamics can greatly differ. The ups and downs in glucose levels can be classified as within-day and between-day glycemic variability (GV [48] . These latter results support the value of GV metrics in predicting major adverse cardiac events and their severity in established T2D [17] . The role of GV was strengthened by the analysis of the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation trial (ADVANCE). This study provided data for a clear association that existed between SD of glucose and all-cause mortality [19] . GV indices, with the exception of the coefficient of variation (%CV), do correlate with mean glucose; thus, it remains uncertain whether GV plays an independent role in the development of diabetes complications. Ratios such as SD/mean glucose x 100 (%CV) or MAGE/mean glucose x 100 might help to circumvent dependence on glucose levels. In clinical practice, SD and IQR can safely be used to sufficiently adjust glycemic stability without enhancing the time in hypoglycemia.
Indices of glucose dynamics
The preceding glucose metrics, including GV, are derived from linear analysis of glucose data; thus, contributing insufficient information to glucose dynamics. A reduced glucose complexity was reported in the transition from normoglycemia to overt diabetes, using detrended fluctuation analysis (DFA) [49] . Likewise, the Poincaré plot analysis of glucose time series is a useful tool to measure temporal glycemic variability, in which the length of the minor SD1 and major SD2 axes of the plot correspond to short-term and long-term variability, respectively. Crenier [50] extended the application of Poincaré plots by validating new metrics, e.g. area and shape of the fitting ellipse. One may speculate whether glucose dynamics, that is glucose complexity, contributes independently to the progress of diabetes complications; however, analyzing glucose time series at multiple time scales would provide a closer approach than using traditional GV indices. Beyond traditional estimates, glucose complexity measures have the potential to assess treatment modalities toward improving the dynamics of the glucoregulatory system. The multiscale entropy (MSE) approach represents a predominating method to characterize the complexity of physiological signals and has recently been introduced for assessment of glucose dynamics (dynamical glucometry) in diabetes [51] .
Glucose monitoring
Although the glucose monitoring techniques have rapidly advanced, self-monitoring of blood glucose (SMBG) with hand-held glucose meters and maintaining tight standards is still the primary technique to assess glycemic control in routine diabetes management [52] . However, SMBG measures single glucose values and provides only snapshots -rapid changes almost escape detection. CGM systems have expanded during recent years, but standardized metrics are still lacking. An expert panel proposed the Ambulatory Glucose Profile (AGP) "Dashbord" and glucose profile summary metrics for better utilization of glucose data in clinical practice [40] . Time in range (TIR), either expressed as "% of glucose readings" or "hours per day", was identified as a key metric for guiding diabetes treatment. The blood glucose range 3.9-10.0 mmol/l was selected for clinical practice as the default target range. If required, individualized targets should be envisaged according to patient age, comorbidities, and compliance. The key metrics agreed upon, are summarized in Table 2 . Although primarily intended for CGM, they can also be used with advanced blood glucose meters. The technology of CGM has become indispensible in the modern management of diabetes by producing glycemic profiles over several days or weeks, real-time glucose values, glucose trends and warnings when glucose values tend to increase to dangerously low or high levels [53] . In principle, the following system variants are available: retrospective (blinded glucose data) and real-time glucose monitoring. Flash glucose monitoring (FGM), a more recent technological development, offers advantages over traditional CGM systems. Regardless which systems is applied, they all require counseling and experience for both health care professionals and patients. Because CGM and FGM systems are based on subcutaneous measurements, the kinetics of the glucose sensing is mainly defined by physiological processes in the subcutaneous space. If glucose sensing is done in the peritoneal space, as recently reported, glucose monitoring can be optimized, because of faster intra-peritoneal kinetics [54] . Preferably, pumptreated patients inclined to hypoglycemia and/or hypoglycemia unawareness will benefit from CGM. FGM circumvents frequent finger-stick glucose measurements by scanning the sensor and is useful for T1D and T2D patients on intensified conventional insulin therapy.
Conclusions
Although glucose monitoring technologies are advancing, HbA1c will continue to be the metric of choice for long-term glycemic control and as a surrogate measure for diabetes complications. But if clinical practice necessitates, it may be supplanted by other parameters. To obviate misinterpretation, HbA1c values should be given both in % and mmol/mol. It is important to take into consideration that glycated serum proteins can be alternative markers under clinical situations, which interfere with HbA1c measurements. In a number of diabetes patients with HbA1c <7% (<53 mmol/mol), indicating apparently good glycemic control, high postmeal incremental glucose values are not unexpected; thus, it is warranted to integrate measurements of pre-meal and PPG into routine diabetes control. Notably GV needs to be integrated into diabetes management. Since the GV metrics are known to be highly interrelated, any currently validated index can be applied for quantification of glucose fluctuations. Commonly used indices are MAGE and SD of glucose; however, %CV is independent of mean glucose and correlates with hypoglycemia. Based on our experience, we recommend mean glucose, TIR and PPG as short-term indicators, for management of glycemic control. In addition to these metrics, we recommend SD of the mean glucose, IQR, and %CV as indices of GV. Nevertheless, a combination of shorter-and longer-term glycemic markers might be preferable for assessment of metabolic control and prediction of vascular outcomes. Finally, glycemic control appears insufficient without integration of dynamic measures. Although current metrics of glucose dynamics cannot be judged at this stage, they have promising potential to obtain more insight into the glucoregulatory mechanisms, hitherto not gained with metrics commonly used.
The importance of GV and/or changes in glucose dynamics remains as yet unclear. However, one should be aware that other factors than simply high blood glucose levels are likely involved in glycemic control and complications of diabetes.
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